Adefovir Is Effective to Promote Development of Immunity to Donor Origin Hepatitis B Virus in an Allogeneic Transplant Recipient: A Case Report

Yaşar, Demet; Suyanı, Elif; Özeni̇rler, Seren; Sucak, Gülsan Türköz

doi:10.1016/j.transproceed.2012.06.082

Transplantation Proceedings

2013

DOI: 10.1016/j.transproceed.2012.06.082

|View full text |Cite

Adefovir Is Effective to Promote Development of Immunity to Donor Origin Hepatitis B Virus in an Allogeneic Transplant Recipient: A Case Report

Demet Yaşar

Elif Suyanı

Seren Özeni̇rler

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2020

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lamivudine

2013

Reactions Weekly

View full text Add to dashboard Cite

S Lamivudine Development of resistance, resulting in hepatitis B reactivation: case reportA 25-year-old man developed lamivudine-resistance, resulting in hepatitis B virus (HBV) reactivation, while receiving lamivudine.The man underwent haematopoietic stem cell transplantation for severe aplastic anaemia. As the donor stem cells were positive for hepatitis B surface antigen, he started receiving lamivudine 100 mg/day before the transplant [route and duration of treatment not stated]. Forty days after the transplant, he had developed hepatitis B surface, core and e antibodies, without experiencing hepatitis. On day +368, however, HBV reactivation was detected, with elevated ALT and AST levels. HBV-DNA levels became positive, with PCR showing a YMMD mutation.The man received adefovir dipivoxil and lamivudine, after which his ALT and AST levels normalised, and his HBV-DNA levels became undetectable. Lamivudine and adefovir dipivoxil were continued for 1 year. At last follow-up, more than 5 years post-transplant, he had no evidence of HBV reactivation.Author comment: "Our patient who was HBV-naïve acquired HBV from his donor and later developed HBV reactivation despite lamivudine treatment apparently due to development of the YMMD mutation. . . prolonged lamivudine treatment which is known to increase the risk of drug resistance (1), apparently lead to a viral mutation resulting in hepatitis B reactivation." Yasar DG, et al. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: A case report.

show abstract

Lamivudine

2013

Reactions Weekly

View full text Add to dashboard Cite

show abstract

A Novel Strategy for the Prevention of Hepatitis B Virus-Related Hepatitis Following Allogeneic Hematopoietic Stem Cell Transplantation from Hepatitis B Surface Antigen-Positive Donors

Shi

Tan

et al. 2020

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The Combined Use of Cytokine-Induced Killer Cells and Cyclosporine A for the Treatment of Aplastic Anemia in a Mouse Model

Liu

Wang²,

Lü³

et al. 2015

Journal of Interferon & Cytokine Research

View full text Add to dashboard Cite

In this study, we investigated the combined use of cytokine-induced killer (CIK) cells and cyclosporine A (CsA) to treat a mouse model of aplastic anemia (AA). CIK cells were cultured and injected alone or in combination with CsA into mice that had previously been induced into AA by busulfan and mouse interferon-γ (IFN-γ). The CIK cell-treated group had a survival rate of 55%, which was similar to the 60% survival rate observed in the CsA-treated group. The combination group showed a survival rate as high as 90%, while none of the mice in the no-treatment group survived to the end of the experiment. The CIK cells produced multiple cytokines, including several hematopoietic growth factors, which could promote the expansion of mouse bone marrow mononuclear cells in vitro. CsA reduced the proportion of CD4(+) T cells and the level of IFN-γ. The combined CIK cell and CsA treatment exhibited the best curative effect, a finding that might be due to the influence of these factors on both hematopoiesis and immunity. These data suggest that the combination of CIK cells and immunosuppressive therapy might be a candidate therapy for AA in the future.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adefovir Is Effective to Promote Development of Immunity to Donor Origin Hepatitis B Virus in an Allogeneic Transplant Recipient: A Case Report

Cited by 3 publications

References 9 publications

Lamivudine

Lamivudine

A Novel Strategy for the Prevention of Hepatitis B Virus-Related Hepatitis Following Allogeneic Hematopoietic Stem Cell Transplantation from Hepatitis B Surface Antigen-Positive Donors

The Combined Use of Cytokine-Induced Killer Cells and Cyclosporine A for the Treatment of Aplastic Anemia in a Mouse Model

Contact Info

Product

Resources

About